ciprofloxacin has been researched along with orbifloxacin in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 22 (44.90) | 29.6817 |
| 2010's | 18 (36.73) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, K; Egawa, H; Fujita, M; Kataoka, M; Matsumoto, J; Minamida, A; Miyamoto, T; Nishimura, Y; Okada, H; Shibamori, K | 1 |
| Chen, S; Cui, S; McDermott, PF; Meng, J; Paulsen, I; White, DG; Zhao, S | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Matsukura, H; Morimura, T; Nobuhara, Y; Ohno, T | 2 |
| Matsukura, H; Morimura, T; Nobuhara, Y | 1 |
| Katae, H; Kitadai, N; Matsumoto, S; Takahashi, M | 1 |
| Aramayona, JJ; Bregante, MA; García, MA; Rueda, S; Solans, C | 1 |
| Katae, H; Matsumoto, S; Nakai, M; Yoshida, M | 1 |
| Baltzley, LK; Brown, MP; Gronwall, RR; Haines, GR; Merritt, KA | 1 |
| Heinen, E | 1 |
| Katz, T; Kay-Mugford, PA; Ngoh, M; Simmons, R; Varma, KJ; Weingarten, AJ; White, A; Zolynas, R | 1 |
| Chomel, BB; Kasten, RW; Labelle, P; Stacy, BA; Wey, AC | 1 |
| Etoré, F; Ganière, JP; Médaille, C | 1 |
| Gaweda, B; Obmińska-Mrukowicz, B; Szczypka, M | 1 |
| Abd El-Aty, AM; Kuroha, M; Nakamura, M; Regmi, NL; Shimoda, M | 1 |
| Davis, JL; Papich, MG; Weingarten, A | 1 |
| Miller, WH; Peters, J; Scott, DW | 1 |
| Abd El-Aty, AM; Kubota, R; Regmi, NL; Shah, SS; Shimoda, M | 1 |
| Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P; Vancraeynest, D | 1 |
| Bensley, D; Fahmy, R; Hoag, SW; O'Brien, C; Tabasi, SH | 2 |
| Abo-El-Sooud, K; Goudah, A | 1 |
| Llorent-Martínez, EJ; Molina-Díaz, A; Ortega-Barrales, P; Ruiz-Medina, A | 1 |
| Abd El-Aty, AM; Chang, BJ; Choi, JH; Goudah, A; Khay, S; Kim, JS; Ko, MW; Lee, CH; Shim, JH; Shin, HC | 1 |
| Chang, ZQ; Cheng, H; Gebru, E; Hwang, MH; Lee, JS; Park, SC | 1 |
| Abd El-Aty, AM; Cho, HJ; Goudah, A; Regmi, NL; Shim, JH; Shimoda, M; Shin, HC | 1 |
| Cho, KH; Elias, G; Hwang, MH; Kim, YH; Lee, JS; Park, SC; Park, YS | 1 |
| Armstrong, RD; Byrne, BA; Hawkins, MG; Taylor, IT; Tell, LA | 1 |
| Cárceles, CM; Corrales, JC; Escudero, E; Fernández-Varón, E; Gómez-Martín, A; Marín, P; Martínez, I | 1 |
| Gebru, E; Kim, JC; Lee, SJ; Park, SC | 1 |
| Choi, MJ; Damte, D; Gebru, E; Kim, YH; Lee, SJ; Park, SC | 1 |
| Tohamy, MA | 1 |
| Harada, K; Kataoka, Y; Shimizu, T; Takahashi, T | 1 |
| Harada, K; Kataoka, Y; Shimizu, T | 1 |
| Cengiz, M; Sahinturk, P | 1 |
| Asai, T; Harada, K; Usui, M | 1 |
| Harada, K; Sasaki, A; Shimizu, T | 1 |
| Bui, CT; Gustafson, DL; Jarosz, KA; Johnston, MS; Watson, MK; Wittenburg, LA | 1 |
| Cazedey, EC; de Araújo, MB; Doriguetto, AC; Freitas, JT; Santos, OM | 1 |
| Greenbarg, EH; Secrest, SA | 1 |
| Harada, K; Shimizu, T | 1 |
| Odoi, A; Oguttu, JW; Qekwana, DN; Sithole, F | 1 |
| Harada, K; Hikasa, Y; Ito, N; Manabe, S; Shimizu, T; Tsukamoto, T | 1 |
| Kong, T; Shi, W; Si, H; Wang, G; Yang, F; Zhang, J | 1 |
| Dennison-Gibby, S; Goller, M; Malka, S | 1 |
| Liu, D; Shao, HT; Song, ZW; Yang, C; Yang, F; Zhang, CS; Zhang, M; Zhang, ZD | 1 |
5 trial(s) available for ciprofloxacin and orbifloxacin
| Article | Year |
|---|---|
The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Drug Administration Schedule; Female; Horses; Infusions, Intravenous; Male; Protein Binding | 2006 |
Lack of inhibitory effects of several fluoroquinolones on cytochrome P-450 3A activities at clinical dosage in dogs.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dogs; Enrofloxacin; Fluoroquinolones; Injections, Intravenous; Male; Microsomes, Liver; Ofloxacin; Quinidine | 2007 |
Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration.
Topics: Animals; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Escherichia coli; Female; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Microbial Sensitivity Tests; Rabbits; Staphylococcus aureus | 2008 |
Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cross-Over Studies; Female; Infusions, Intravenous; Injections, Intramuscular; Klebsiella pneumoniae; Lactation; Milk; Sheep | 2009 |
Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Chromatography, High Pressure Liquid; Ciprofloxacin; Coturnix; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Escherichia coli; Female; Injections, Intravenous; Male; Microbial Sensitivity Tests; Pasteurella; Staphylococcus | 2011 |
44 other study(ies) available for ciprofloxacin and orbifloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Molecular Conformation; Phenylbutyrates; Pseudomonas Infections; Rats; Streptococcal Infections; Structure-Activity Relationship; Theophylline; X-Ray Diffraction | 1990 |
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
Topics: Animals; Anti-Infective Agents; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Gene Targeting; Genes, Bacterial; Mutation; Salmonella Infections, Animal; Salmonella typhimurium | 2007 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Photodegradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution.
Topics: Anti-Infective Agents; Buffers; Ciprofloxacin; Decarboxylation; Hydrogen-Ion Concentration; Kinetics; Photochemistry; Solutions | 1995 |
Degradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution.
Topics: Anti-Infective Agents; Buffers; Ciprofloxacin; Hydrogen-Ion Concentration; Solutions; Temperature | 1995 |
Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Magnetic Resonance Spectroscopy; Photochemistry; Solutions | 1997 |
A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin.
Topics: Animals; Anti-Bacterial Agents; Cats; Chromatography, High Pressure Liquid; Ciprofloxacin; Dogs; Mass Spectrometry; Microbial Sensitivity Tests | 1998 |
Determination of orbifloxacin in rabbit plasma by high-performance liquid chromatography with fluorescence detection.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Rabbits; Sensitivity and Specificity | 1999 |
A study of metabolites isolated from urine samples of pigs and calves administered orbifloxacin.
Topics: Animals; Anti-Infective Agents; Cattle; Chromatography, High Pressure Liquid; Ciprofloxacin; Female; Injections, Intramuscular; Male; Species Specificity; Swine | 1999 |
Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares.
Topics: Animals; Area Under Curve; Ascitic Fluid; Bacteria; Body Fluids; Ciprofloxacin; Endometrium; Female; Half-Life; Horses; Intestinal Absorption; Microbial Sensitivity Tests; Synovial Fluid; Tissue Distribution | 2001 |
Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Dogs; Enrofloxacin; Female; Fluoroquinolones; Male; Microbial Sensitivity Tests; Quinolones | 2002 |
Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Ciprofloxacin; Dog Diseases; Dogs; Drug Administration Schedule; Female; Male; Pyoderma; Skin; Tissue Distribution; Treatment Outcome | 2002 |
Fatal case of endocarditis associated with Bartonella henselae type I infection in a domestic cat.
Topics: Animals; Anti-Bacterial Agents; Bartonella henselae; Cat Diseases; Cat-Scratch Disease; Cats; Ciprofloxacin; Fatal Outcome; Female; Ovariectomy | 2003 |
In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Otitis Externa; Pyoderma; Staphylococcal Skin Infections; Staphylococcus | 2004 |
Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice.
Topics: Animals; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Interleukin-1; Macrophages, Peritoneal; Mice; Nitric Oxide; T-Lymphocyte Subsets; Thymus Gland | 2005 |
Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP1A1; Dogs; Drug Interactions; Enrofloxacin; Fluoroquinolones; Male; Microsomes, Liver; Norfloxacin; Ofloxacin | 2005 |
Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dog Diseases; Dogs; Female; Male; Pyoderma; Staphylococcal Infections; Time Factors; Treatment Outcome | 2006 |
Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross-Over Studies; Female; Goats; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Kinetics; Lactation; Milk | 2007 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
Quality by design, part I: application of NIR spectroscopy to monitor tablet manufacturing process.
Topics: Anti-Bacterial Agents; Calibration; Chemistry, Pharmaceutical; Ciprofloxacin; Feasibility Studies; Materials Testing; Multivariate Analysis; Quality Control; Spectroscopy, Near-Infrared; Tablets | 2008 |
Pharmacokinetics and milk penetration of orbifloxacin after intravenous and intramuscular injections to dromedary lactating camels (Camelus dromedaries).
Topics: Animals; Anti-Infective Agents; Area Under Curve; Biological Availability; Camelus; Ciprofloxacin; Female; Half-Life; Injections, Intramuscular; Injections, Intravenous; Lactation; Milk | 2008 |
Quality by design, part III: study of curing process of sustained release coated products using NIR spectroscopy.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Delayed-Action Preparations; Quality Control; Spectroscopy, Near-Infrared; Tablets | 2008 |
Implementation of terbium-sensitized luminescence in sequential-injection analysis for automatic analysis of orbifloxacin.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dogs; Flow Injection Analysis; Horses; Luminescent Measurements; Resins, Synthetic; Terbium; Veterinary Drugs | 2008 |
Approaches for application of sub and supercritical fluid extraction for quantification of orbifloxacin from plasma and milk: application to disposition kinetics.
Topics: Analytic Sample Preparation Methods; Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; Ciprofloxacin; Deer; Female; Green Chemistry Technology; Injections, Intramuscular; Injections, Intravenous; Kinetics; Lactation; Milk; Pressure; Reproducibility of Results; Temperature; Time Factors | 2009 |
Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Dogs; Escherichia coli; Injections, Intramuscular; Injections, Intravenous; Microbial Sensitivity Tests; Proteus mirabilis; Staphylococcus; Staphylococcus aureus | 2009 |
Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cattle; Chromatography, High Pressure Liquid; Ciprofloxacin; Escherichia coli; Female; Injections, Intramuscular; Injections, Intravenous; Mannheimia haemolytica; Microbial Sensitivity Tests; Protein Binding; Serum Bactericidal Test; Staphylococcus aureus | 2009 |
Short communication: Fluoroquinolone susceptibility of Staphylococcus aureus strains isolated from caprine clinical mastitis in southeast Spain.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Female; Fluoroquinolones; Goat Diseases; Goats; Mastitis; Microbial Sensitivity Tests; Milk; Spain; Staphylococcus aureus | 2010 |
Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Ciprofloxacin; Female; Half-Life; Male; Mammals; Regression Analysis; Retrospective Studies | 2011 |
Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Base Sequence; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Enrofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation | 2012 |
Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Ducks; Injections, Intramuscular; Injections, Intravenous; Kinetics; Models, Biological; Pasteurella Infections; Pasteurella multocida; Poultry Diseases | 2011 |
Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dogs; Enrofloxacin; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2012 |
Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Escherichia coli; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus | 2013 |
Assessment of synergistic interactions of danofloxacin and orbifloxacin against quinolone-resistant Escherichia coli isolated from animals by the checkerboard and time-kill methods.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones | 2013 |
Application of enrofloxacin and orbifloxacin disks approved in Japan for susceptibility testing of representative veterinary respiratory pathogens.
Topics: Actinobacillus pleuropneumoniae; Anti-Bacterial Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resistance, Bacterial; Enrofloxacin; Fluoroquinolones; Japan; Mannheimia haemolytica; Pasteurella multocida | 2014 |
Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot study.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Cats; Chromatography, High Pressure Liquid; Ciprofloxacin; Citrobacter freundii; Drug Resistance, Bacterial; Escherichia coli; Feces; Pilot Projects | 2016 |
Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus).
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Chromatography, Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Infusions, Intravenous; Mass Spectrometry; Rabbits; Random Allocation | 2015 |
Structure, Solubility and Stability of Orbifloxacin Crystal Forms: Hemihydrate versus Anhydrate.
Topics: Biological Availability; Chemistry, Pharmaceutical; Ciprofloxacin; Crystallization; Fluoroquinolones; Molecular Structure; Solubility; Water | 2016 |
What Is Your Diagnosis? Fungal pneumonia and aspergillosis.
Topics: Air Sacs; Animals; Anti-Infective Agents; Aspergillosis; Bird Diseases; Ciprofloxacin; Diagnosis, Differential; Eagles; Enrofloxacin; Female; Fluid Therapy; Fluoroquinolones; Iron-Dextran Complex; Radiography, Thoracic; Respiratory Tract Infections; Vitamin B Complex | 2016 |
Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Disease Eradication; Dog Diseases; Dogs; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2017 |
Patterns and predictors of antimicrobial resistance among Staphylococcus spp. from canine clinical cases presented at a veterinary academic hospital in South Africa.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Dog Diseases; Dogs; Doxycycline; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Enrofloxacin; Female; Fluoroquinolones; Hospitals, Animal; Kanamycin; Lincomycin; Male; Retrospective Studies; South Africa; Spectinomycin; Staphylococcal Infections; Staphylococcus; Trimethoprim, Sulfamethoxazole Drug Combination; Tylosin | 2017 |
Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dogs; Escherichia coli; Gas Chromatography-Mass Spectrometry; Klebsiella pneumoniae; Microbial Sensitivity Tests; Proteus mirabilis; Pseudomonas aeruginosa; Staphylococcus; Urinary Tract | 2017 |
Development of a multiroute physiologically based pharmacokinetic model for orbifloxacin in rabbits.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Ciprofloxacin; Female; Injections, Intramuscular; Injections, Intravenous; Kidney; Liver; Male; Models, Biological; Muscle, Skeletal; Myocardium; Rabbits | 2018 |
Septic Arthritis and Osteomyelitis Caused by
Topics: Animals; Anseriformes; Anti-Bacterial Agents; Arthritis, Infectious; Bird Diseases; Charadriiformes; Chryseobacterium; Ciprofloxacin; Female; Flavobacteriaceae Infections; Male; Osteomyelitis | 2020 |
Development and application of a physiologically based pharmacokinetic model for orbifloxacin in crucian carp (Carassius auratus).
Topics: Animals; Anti-Bacterial Agents; Carps; Ciprofloxacin; Goldfish; Models, Biological | 2022 |